祥生医疗(688358) - 2024 Q3 - 季度财报

Financial Performance - Revenue for Q3 2024 was CNY 114,675,131.79, an increase of 8.79% year-over-year[2] - Net profit attributable to shareholders for Q3 2024 was CNY 17,064,907.80, a decrease of 42.09% year-over-year[2] - Net profit excluding non-recurring gains and losses for Q3 2024 was CNY 15,062,993.05, down 39.13% year-over-year[2] - Basic earnings per share for Q3 2024 were CNY 0.15, a decrease of 42.31% year-over-year[3] - The weighted average return on equity for Q3 2024 was 1.25%, a decrease of 0.91 percentage points year-over-year[3] - Net profit for the third quarter of 2024 was CNY 98,408,552.70, down 30.4% from CNY 141,432,208.56 in the previous year[19] - The total comprehensive income for the third quarter of 2024 was CNY 95,081,639.04, down from CNY 141,602,414.23 in the previous year[20] Cash Flow and Liquidity - Operating cash flow for Q3 2024 was CNY 16,363,001.78, an increase of 36.80% year-over-year[2] - The company's cash and cash equivalents as of September 30, 2024, amount to ¥951,228,143.05, an increase from ¥688,772,839.29 as of December 31, 2023, reflecting a growth of approximately 38.1%[13] - Net cash flow from operating activities for the first three quarters of 2024 was ¥70,624,175.74, up 48.7% from ¥47,503,874.22 in 2023[22] - The net increase in cash and cash equivalents for the first three quarters of 2024 was ¥526,483,394.87, compared to ¥184,825,770.15 in 2023, representing an increase of 184.5%[23] - The ending balance of cash and cash equivalents as of the end of the third quarter of 2024 was ¥730,501,794.52, up from ¥624,310,886.28 in 2023[23] Assets and Liabilities - Total assets at the end of Q3 2024 were CNY 1,586,685,740.10, a 4.22% increase from the end of the previous year[3] - The company's total liabilities increased to CNY 210,947,277.88, compared to CNY 153,419,489.68 in the previous year, reflecting a significant rise in financial obligations[17] - The total equity attributable to shareholders reached CNY 1,375,738,462.22, up from CNY 1,369,068,613.10 year-on-year[17] - Total current assets reached ¥1,409,841,502.17, compared to ¥1,341,325,853.87 in the previous period, marking an increase of approximately 5.1%[15] Research and Development - R&D investment for Q3 2024 was CNY 22,690,504.23, accounting for 19.79% of revenue, a decrease of 0.39 percentage points year-over-year[3] - Research and development expenses for the first three quarters of 2024 were CNY 61,760,390.24, an increase of 4.9% compared to CNY 58,937,647.88 in the same period of 2023[18] Shareholder Information - The total number of common shareholders at the end of the reporting period is 5,170, with the largest shareholder, Wuxi Xiangsheng Investment Co., Ltd., holding 45,360,000 shares, representing 40.46% of the total shares[8] - The number of shares held by the top ten shareholders includes significant stakes from Wuxi Xiangsheng Investment Co., Ltd. and Mo Ruoli, holding 40.46% and 23.60% respectively[8] - The company has not reported any changes in the participation of major shareholders in margin trading or securities lending activities[12] Operating Costs - Total operating costs increased to CNY 265,916,746.04, up 3.3% from CNY 257,202,310.53 year-on-year[18] - The company experienced increased personnel costs and rental expenses due to accelerated marketing system development, impacting net profit[6] Other Financial Metrics - The company reported an investment income of CNY 4,784,941.62, a decrease from CNY 9,704,644.61 in the previous year[19] - Other comprehensive income after tax was CNY -3,326,913.66, compared to CNY 170,205.67 in the same period last year[20] - Cash paid for purchasing goods and services decreased to ¥143,629,153.20 in 2024 from ¥154,954,131.42 in 2023, a decline of 7.3%[22] - Cash paid for taxes increased to ¥24,885,612.16 in 2024 from ¥20,120,991.57 in 2023, reflecting a rise of 23.5%[22]